Physician profile
Timothy Mark Jochen
NPI 1083748461
$80,822.17
in general payments reported to CMS, 2019-2025
20 companies · $2,674 in 2025
The $2,674 reported for 2025 was more than what 82% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $371 · 2021: $13K · 2022: $45K · 2023: $11K · 2024: $7,607 · 2025: $2,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $2,712 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,613.15 |
| Food and Beverage | $2,711.87 |
| Education | $127.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $57,626.29 | 2019-2023 | |
| Abbvie INC. | $19,895.88 | 2019-2025 | |
| Galderma Laboratories, L.P. | $785.34 | 2020-2025 | Dysport, Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $623.25 | 2019-2025 | |
| Revance Therapeutics, INC. | $544.58 | 2024-2025 | Daxxify |
| Pfizer INC. | $335.87 | 2019-2023 | |
| Lilly USA, LLC | $170.92 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $161.91 | 2022-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $121.24 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $116.31 | 2021-2025 | Blu-U |
| Genzyme Corporation | $93.83 | 2019-2022 | |
| Organogenesis INC. | $89.18 | 2024-2025 | Nushield, Cygnus Dual |
| Regeneron Healthcare Solutions, INC. | $83.06 | 2021-2023 | Libtayo |
| Incyte Corporation | $43.35 | 2021-2023 | Opzelura |
| Verrica Pharmaceuticals INC. | $36.55 | 2025 | Ycanth |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.91 | 2022 | |
| Leo Pharma INC. | $19.92 | 2022 | |
| Ucb, INC. | $19.36 | 2025 | Bimzelx |
| Strata Skin Sciences, INC. | $17.62 | 2025 | Xtrac |
| Apyx Medical Corporation | $2.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Jochen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.